Development of positron emission tomography β-Amyloid plaque imaging agents

Seminars in Nuclear Medicine

Volumn 42, Issue 6, 2012, Pages 423-432

  Mathis, Chester A ^a,b   Mason, N Scott ^a   Lopresti, Brian J ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AZD 4694; CONGO RED; FLORBETAPIR F 18; FLUORESCENT DYE; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B; RACLOPRIDE C 11; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SB 13; THIOFLAVINE; UNCLASSIFIED DRUG; X 34;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CHEMICAL MODIFICATION; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROFIBRILLARY TANGLE; NONHUMAN; PHARMACOPHORE; POSITRON EMISSION TOMOGRAPHY; STAIN;

EID: 84869021291     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.07.001     Document Type: Review

References (94)

1. Klunk WE, Debnath ML, Pettegrew JW: Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 1994;15:691-698
2. Mathis CA, Mahmood K, Debnath ML, et al: Synthesis of a lipophilic radioiodinated ligand with high affinity to amyloid protein in Alzheimer's disease brain tissue. J Label Comp Radiopharm 1997;40:94-95 (abstract)
3. Mathis CA, Wang Y, Klunk WE: Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 2004;10:1469-1492
4. Alzheimer A: Uber eine eigenartige erkrankung der hirnrinde [About a peculiar disease of the cerebral cortex] [in German]. Allgemeine Zeitschrift fur Psychiatrie und Pyschisch-Gerichtlich Medizin 1907;64: 146-148
5. Klunk WE, Debnath ML, Pettegrew JW: Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe. Neurobiol Aging 1995;16:541-548
6. Dishino DD, Welch MJ, Kilbourn MR, et al: Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 1983;24:1030-1038
7. Waterhouse RN: Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003;5:376-389
8. Styren SD, Hamilton RL, Styren GC, et al: X-34, a fluorescent derivative of Congo red: A novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 2000;48:1223-1232
9. Klunk WE, Jacob RF, Mason RP: Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-Abeta) spectrophotometric assay. Anal Biochem 1999;266:66-76
10. Farde L, Hall H, Ehrin E, et al: Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231: 258-261
11. Hsiao K, Chapman P, Nilsen S, et al: Correlative memory deficits, A elevation, and amyloid plaques in transgenic mice. Science 1996;274: 99-103
12. Klunk WE, Debnath ML, Koros AM, et al: Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci 1998;63:1807-1814
13. Ishii K, Klunk WE, Arawaka S, et al: Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice. Neurosci Lett 2002;333:5-8
14. Ikonomovic MD, Abrahamson EE, Isanski BA, et al: X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol 2006;412:123-144
15. Klunk WE, Bacskai BJ, Mathis CA, et al: Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002;61:797-805
16. Brendza RP, Bacskai BJ, Cirrito JR, et al: Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005;115:428-433
17. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al: Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008;451:720-724
18. Burgold S, Bittner T, Dorostkar MM, et al: In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol 2011;121:327-335
19. Sadowski M, Pankiewicz J, Scholtzova H, et al: Targeting prion amyloid deposits in vivo. J Neuropathol Exp Neurol 2004;63:775-784
20. Skovronsky DM, Zhang B, Kung MP, et al: In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:7609-7614
21. Maezawa I, Hong HS, Liu R, et al: Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem 2008;104:457-468
22. Klunk WE, Wang Y, Huang GF, et al: Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;200:1471-1484
23. Mathis CA, Bacskai BJ, Kajdasz ST, et al: A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12:295-298
24. Mathis CA, Wang Y, Holt DP, et al: Synthesis and evaluation of 11Clabeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754
25. Klunk WE, Lopresti BJ, Ikonomovic MD, et al: Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-10606
26. Ikonomovic MD, Klunk WE, Abrahamson EE, et al: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-1645
27. Phelps ME, Barrio JR: Correlation of brain amyloid with "aerobic glycolysis": A question of assumptions? Proc Natl Acad Sci USA 2010;107: 17459-17460
28. Mathis CA, Holt DP, Wang Y, et al: Species-dependent metabolism of the amyloid imaging agent [C-11]PIB. J Nucl Med 2004;45:114P (abstract)
29. Maeda J, Ji B, Irie T, et al: Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007;27:10957-10968
30. Manook A, Yousefi BH, Willuweit A, et al: Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 2012;7: e31310
31. Bergström M, Grahnén A, Långström B: Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003;59:357-366
32. Mills G: The exploratory IND. J Nucl Med 2008;49:45N-47N
33. Klunk WE, Mathis CA: Whatever happened to Pittsburgh compound- A? Alzheimer Dis Assoc Disord 2008;22:198-203
34. Klunk WE, Engler H, Nordberg A, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319
35. Kadir A, Marutle A, Gonzalez D, et al: Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011;134:301-317
36. Arnold SE, Hyman BT, Flory J, et al: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103-116
37. Braak H, Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-357
38. Thal DR, Rüb U, Schultz C, et al: Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000; 59:733-748
39. Engler H, Blomqvist G, Bergstrom M, et al: First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging 2002;23(suppl):1568 (abstract)
40. Bacskai BJ, Frosch MP, Freeman SH, et al: Molecular imaging with Pittsburgh compound B confirmed at autopsy: A case report. Arch Neurol 2007;64:431-434
41. Ikonomovic MD, Abrahamson EE, Price JC, et al: Early AD pathology in a [C-11]PiB-negative case: A PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 2012;12:433-447
42. Mintun MA, Larossa GN, Sheline YI, et al: [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452
43. Pike KE, Savage G, Villemagne VL, et al: -amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-2844
44. Aizenstein HJ, Nebes RD, Saxton JA, et al: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517
45. Pike KE, Ellis KA, Villemagne VL, et al: Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia 2011;49:2384-2390
46. Forsberg A, Engler H, Almkvist O, et al: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465
47. Kemppainen NM, Aalto S, Wilson IA, et al: PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603-1606
48. Wolk DA, Price JC, Saxton JA, et al: Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557-568
49. Okello A, Koivunen J, Edison P, et al: Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 2009;73:754-760
50. Villemagne VL, Pike KE, Chételat G, et al: Longitudinal assessment of A and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69:181-192
51. Koivunen J, Scheinin N, Virta JR, et al: Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study. Neurology 2011;76:1085-1090
52. Rowe CC, Ng S, Ackermann U, et al: Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-1725
53. Jack CR Jr, Lowe VJ, Senjem ML, et al: 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680
54. Fodero-Tavoletti MT, Cappai R, McLean CA, et al: Amyloid imaging in Alzheimer's disease and other dementias. Brain Imaging Behav 2009; 3:246-261
55. Kadir A, Almkvist O, Forsberg A, et al: Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012;33:198e1-198e14
56. Theuns J, Marjaux E, Vandenbulcke M, et al: Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mutat 2006;27:888-896
57. Klunk WE, Price JC, Mathis CA, et al: Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174-6184
58. Remes AM, Laru L, Tuominen H, et al: Carbon 11-labeled Pittsburgh Compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008;65:540-544
59. Villemagne VL, Pike K, Pejoska S, et al: 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): A case report. J Alzheimers Dis 2010;19:423-428
60. Johansson A, Savitcheva I, Forsberg A, et al: [(11)C]-PIB imaging in patients with Parkinson's disease: Preliminary results. Parkinsonism Relat Disord 2008;14:345-347
61. Rabinovici GD, Furst AJ, O'Neil JP, et al: 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68:1205-1212
62. Drzezga A, Grimmer T, Henriksen G, et al: Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008;39:619-633
63. Maetzler W, Reimold M, Liepelt I, et al: [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39:1027-1033
64. Rabinovici GD, Rosen HJ, Alkalay A, et al: Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011;77:2034-2042
65. Leyton CE, Villemagne VL, Savage S, et al: Subtypes of progressive aphasia: Application of the International Consensus Criteria and validation using -amyloid imaging. Brain 2011;134:3030-3043
66. Caso F, Gesierich B, Henry M, et al: Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. Behav Neurol 2012 Apr 24. [Epub ahead of print]
67. Rinne JO, Brooks DJ, Rossor MN, et al: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebocontrolled, ascending-dose study. Lancet Neurol 2010;9:363-372
68. Ostrowitzki S, Deptula D, Thurfjell L, et al: Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198-207
69. Rowe CC, Ellis KA, Rimajova M, et al: Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-1283
70. Jagust WJ, Bandy D, Chen K, et al: The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221-229
71. Klunk WE: Amyloid imaging as a biomarker for cerebral -amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011; 32(suppl 1):S20-S36
72. Sperling RA, Aisen PS, Beckett LA, et al: Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280- 292
73. Mathis CA, Lopresti B, Mason N, et al: Comparison of the amyloid imaging agents [F-18]3'-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects. J Nucl Med 2007;48:56P (abstract)
74. Vandenberghe R, Van Laere K, Ivanoiu A, et al: 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 2010;68:319-329
75. Thurfjell L, Lötjönen J, Lundqvist R, et al: Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis 2012;10:246-249
76. Verhoeff NP, Wilson AA, Takeshita S, et al: In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584-595
77. Rowe CC, Ackerman U, Browne W, et al: Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 2008;7:129-135
78. Barthel H, Luthardt J, Becker G, et al: Individualized quantification of brain -amyloid burden: Results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 2011;38:1702-1714
79. Barthel H, Gertz HJ, Dresel S, et al: Cerebral amyloid- PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 2011;10: 424-435
80. Wong DF, Rosenberg PB, Zhou Y, et al: In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913-920
81. Choi SR, Schneider JA, Bennett DA, et al: Correlation of amyloid PET ligand florbetapir F 18 binding with A aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 2012;26:8-16
82. Clark CM, Pontecorvo MJ, Beach TG, et al: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- plaques: A prospective cohort study. Lancet Neurol 2012; 11:669-678
83. Joshi AD, Pontecorvo MJ, Clark CM, et al: Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378-384
84. Cselényi Z, Jönhagen ME, Forsberg A, et al: Clinical validation of 18FAZD4694, an amyloid-specific PET radioligand. J Nucl Med 2012; 53:415-424
85. Jagust WJ: Amyloid imaging: Liberal or conservative? Let the data decide. Arch Neurol 2011;68:1377-1378 (editorial)
86. Villemagne VL, Mulligan RS, Pejoska S, et al: Comparison of 11C-PiB and 18F-florbetaben for A imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39:983-989
87. Hsiao IT, Huang CC, Hsieh CJ, et al: Correlation of early-phase 18Fflorbetapir (AV-45/Amyvid) PET images to FDG images: Preliminary studies. Eur J Nucl Med Mol Imaging 2012;39:613-620
88. FDA approves 18F-florbetapir PET agent. J Nucl Med 2012;53:15N (editorial)
89. Sperling RA, Johnson KA: Dementia: New criteria but no new treatments. Lancet Neurol 2012;11:4-5 (editorial)
90. Jack CR Jr, Knopman DS, Jagust WJ, et al: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128
91. Jack CR Jr, Vemuri P, Wiste HJ, et al: Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68:1526-1535
92. Sperling RA, Jack CR Jr, Aisen PS: Testing the right target and right drug at the right stage. Sci Transl Med 2011;3:111 (editorial)
93. Fodero-Tavoletti MT, Okamura N, Furumoto S, et al: 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011; 134:1089-1100
94. Zhang W, Arteaga J, Cashion DK, et al: A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 2012 Jun 8. [Epub ahead of print]